Posts Tagged ‘graft’

BBC News – Chemical found which ‘makes bone marrow repair skin’

In ALL ARTICLES on April 6, 2011 at 2:06 pm

‘Chemical found which ‘makes bone marrow repair skin’

Healing skin graft
Skin grafts trigger repair by bone marrow cells

The chemical which summons stem cells from bone marrow to the site of a wound has been discovered by scientists in the UK and Japan.

The study, published in Proceedings of the National Academy of Sciences, identified the distress signal – HMGB1.

The authors believe it can be used to put “a megaphone in the system” to improve the treatment of injuries such as burns and leg ulcers.

Another UK expert said the research had potential.

Bone marrow was thought to play a role in repairing damaged skin, but the exact process was unknown.


Scientists at Osaka University and King’s College London gave mice bone marrow cells that glow green – which can be tracked while moving round the body…

BBC News – Chemical found which ‘makes bone marrow repair skin’.

Eyes on the Road; Hands on the Wheel: OSIR, EFII, HEV : Small Cap Stock Analysis : Small Cap Stocks and Penny Stocks For Big Returns – SmallCap Network

In BUSINESS OF STEM CELLS on July 26, 2010 at 5:58 pm

What’s it all about?

Osiris is utilizing smart marketing technique and business strategy by first dipping their foot into the shallow end of the stem cell therapy pool.

They want to treat Heart, Diabetes, GI and joints with their stem cell product “Prochymal” so they are wisely starting by treating graft versue host disease (GVHD) in bone marrow transplant (BMT) recipients.

[Standard treatment for GVHD is corticosteroids (used to suppress the T-cell mediated immune onslaught on the host tissues).] 

This really won’t ruffle too many pharma feathers and BMT’s and GVHD have a ~40 year history.  Then they piggy back diabetes, heart, crohn’s, etc on top of the approval for the GVHD treatment .  Wise move.  I hope it works! – dg]



Osiris Therapeutics (OSIR) Climbs on Regulatory Milestone

By Dennis Askew – Published: July 26, 2010 9:06:08 AM PDT

OSIR: Health Canada Grants Priority Review for Stem Cell Therapy

First up this morning we have Osiris Therapeutics Inc., (OSIR) http://www.osiristx.com/ currently trading in the $7.79 range on a 3-Month average daily trading volume of 108,303 shares. OSIR has a 52-week high of $15.20 set on 08-27-09 with current trailing twelve month revenues of $43+ million and a positive, corresponding diluted EPS of +$0.07. I like those earnings.

Last week the Biologics and Genetic Therapies Directorate of Health Canada completed its initial evaluation and accepted for full review OSIR’s New Drug Submission of Prochymal, an adult stem cell therapy for the treatment of graft vs. host disease.

[Graft-versus-host disease (GVHD) is a common complication of allogeneic bone marrow transplantation in which functional immune cells in the transplanted marrow recognize the recipient as “foreign” and mount an immunologic attack. It can also take place in a blood transfusion under certain circumstances. – wiki

Side note: GVHD is virtually eliminated when using autologous (from the patient’s own body) stem cells for treatments. -dg]

Based on a separate review of summary clinical data, Health Canada notified OSIR that the application has been granted Priority Review, shortening the examination period from 300 to 180 days. If successful, Prochymal would become the world’s first approved stem cell therapy.

[“the world’s first approved stem cell therapy” Not quite right:

  1. There are already dozens if not hundreds of approved THERAPIES in the world going back over half a decade….
  2. What is Prochymal, then? Prochymal is an allogenic (from a donor) , ex vivo (outside the organism) cultured  batch of mesenchymal (bone marrow) stem cells implanted into the patient who has received a bone marrow transplant in the interest of suppressing his immune response so the new/foreign bone marrow can take seed.
  3. So…Prochymal may become the first stem cells derived from (allogenic) outside sources and cultured (ex vivo) in a dish to be approved for use in a human patients with GVHD…IN THE USA.
  4. In related news; in September of 2009, Stemedica (a different company) was granted a license to manufacture stem cells for therapiesStemedica Licensed to Manufacture Clinical Grade Stem Cells

– dg]

Prochymal, which is in Phase III clinical trials for the treatment of acute and steroid refractory graft versus host disease and Crohn’s disease, as well as for the repair of gastrointestinal injury resulting from radiation exposure. OSIR is also developing its Prochymal drug candidate for the repair of heart tissue following a heart attack, and for the protection of pancreatic islet cells in patients with type 1 diabetes.

OSIR is also developing Chondrogen, a biologic drug candidate for the treatment of osteoarthritis and the reduction of pain in the knee. At nearly 50% off its high, returning ttm earnings, and making product-to-market strides, OSIR is a long-term (1 Yr) ‘Buy’ consideration for me.

via Eyes on the Road; Hands on the Wheel: OSIR, EFII, HEV : Small Cap Stock Analysis : Small Cap Stocks and Penny Stocks For Big Returns – SmallCap Network.

Adult Stem Cell Grafts Help Paralyzed Heal

In VICTORIES & SUCCESS STORIES on October 21, 2009 at 4:43 am

Wayne State Study Shows Adult Stem Cell Grafts Help Paralyzed

A new study by a Wayne State University School of Medicine researcher details the outcome of adult stem cell grafts in spinal cord injuries and how the procedure led to increased mobility and quality of life for patients.

Spinal cord injury
A severe spinal cord injury often causes loss of feeling and paralysis, the loss of movement and voluntary control over the muscles in the body. Spinal cord damage also causes loss of reflex function below the point of injury interrupting bodily functions such as breathing, bowel control, and bladder control. In the event of a spinal injury prompt medical attention can help to minimize further spinal cord damage.
Associate Professor Jean Peduzzi-Nelson of the Department of Anatomy and Cell Biology conducted the study, “Olfactory Mucosal Autografts and Rehabilitation for Chronic Traumatic Spinal Cord Injury,” which was published online in the journal Neurorehabilitation and Neural Repair.
The process involves the use of adult stem-like progenitor cells in the patient’s own nasal tissue. The use of a person’s own stem cells, Peduzzi-Nelson said, lessens the problems of rejection, tumor formation and disease transmission.

Spinal Cord Injury
In the study, 20 patients with severe chronic spinal cord injuries received a treatment combination of partial scar removal, transplantation of nasal tissue containing stem cells to the site of the spinal cord injury and rehabilitation. All of the patients had total paralysis below the level of their spinal cord injury before the treatment.
“This may be the first clinical study of patients with severe, chronic spinal cord injury to report considerable functional improvement in some patients with a combination treatment,” Peduzzi-Nelson said. “Normally, in people with spinal cord injuries that happened more than 18 months ago, there is little improvement.”
The injuries in the study patients were 18 months to 15 years old. The patients, ages 19 to 37, had no use of their legs before the treatment. One paraplegic treated almost three years after the injury now ambulates with two crutches and knee braces. Ten other patients ambulate with physical assistance and walkers (with and without braces). One 31-year-old male tetriplegic patient uses a walker without the help of knee braces or physical assistance. When the stem cell transplant and scar removal process was combined with an advanced form of rehabilitative training that employs brain-initiated weight-bearing movement, 13 patients improved in the standard measures used to assess functional independence and walking capabilities.

“We concluded that olfactory mucosal autograft is feasible, relatively safe and possibly beneficial in people with chronic spinal cord injury when combined with post-operative rehabilitation,” Peduzzi-Nelson said. “There are clear indications of efficacy based on neurological, functional and electrophysiological testing that justify moving forward to a larger, controlled clinical trial. In patients who are willing to commit to lots of intense rehabilitation, this combination treatment holds promise to improve their condition.”
Peduzzi-Nelson noted that there are many sources of stem cells in the body, including bone marrow, fat and the brain, but that the olfactory mucosa is the only suitable tissue that can be easily obtained with minimally invasive procedures.
Spinal Cord Injury
The stem-like progenitor cells in the olfactory mucosa are special because they normally form new neurons more rapidly than cells from any other place in the adult nervous system. When such cells are transplanted into chick embryos, she said, the cells can form mature cells of the heart, trunk muscles, liver, brain and spinal cord. This suggests that olfactory stem-like progenitor cells are very immature and capable of forming a variety of cell types.
  • The partial scar removal and tissue transplantation procedures were performed in Portugal. The rehabilitation of patients took place in Italy and Portugal.
  • “Many patients in the Detroit area have had this procedure,” she said. “Along with some colleagues, I have sent questionnaires to these local patients to find out whether or not there are any side-effects or functional improvement.”
  • Peduzzi-Nelson said that she and Jay Meythaler, M.D., chairman of the Department of Physical Medicine and Rehabilitation, along with other colleagues, are seeking FDA approval to perform the procedure in the United States.

BEAUTY OF SCIENCE – Skin stem cell replenish

In SCIENCE & STEM CELLS on October 8, 2009 at 5:27 pm

Skin deep. In a skin grafting experiment, skin with TCF3 and TCF4 (top), unlike skin without the two proteins (bottom), can activate epidermal stem cells to replenish skin cells on the surface that have died and flaked off. (Credit: Image courtesy of Rockefeller University)

via Two Proteins Enable Skin Cells To Regenerate.

%d bloggers like this: